share_log

Reported Earlier, MediciNova Receives Notice Of Allowance From Japan Patent Office For MN-166 In Macular Injury Treatment

Reported Earlier, MediciNova Receives Notice Of Allowance From Japan Patent Office For MN-166 In Macular Injury Treatment

早些時候報道，MediciNova 收到了日本專利局批准黃斑損傷治療的 MN-166 的通知
Benzinga ·  03/27 14:40

Once issued, this patent is expected to expire no earlier than October 2039. The allowed claims cover the use of MN-166 (ibudilast) for treating macular injury associated with progressive multiple sclerosis and for decreasing macular volume loss associated with progressive multiple sclerosis.

該專利一旦頒發，預計將不早於2039年10月到期。允許的索賠涵蓋使用 MN-166（ibudilast）治療與進行性多發性硬化症相關的黃斑損傷以及減少與進行性多發性硬化症相關的黃斑體積流失。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論